Huntington’s Disease
Jang-Ho J. Cha and Anne B. Young
REFERENCES
Albin RL and Greenamyre JT (1992). Alternative
excitotoxic hypotheses. Neurology
42:733-738.
Albin RL, Reiner A, Anderson KD, D'Amato
CJ, Penney JB, and Young AB (1988). Juvenile onset Huntington's disease: Two
cases studied with immunocytochemistry, cholinesterase histochemistry, and
autoradiography. Neurology 38:360.
Albin Rl, Reiner A, Anderson KD, Dure LS,
Handelin B, Balfour R, Whetsell WO, Jr., Penney JB, and Young AB (1992). Preferential
loss of striato-external pallidal projection neurons in presymptomatic Huntington's
disease. Ann. Neurol. 31:425-430.
Albin RL, Reiner A, Anderson KD, Penney
JB, and Young AB (1990). Striatal and nigral neuron subpopulations in rigid
Huntington's disease: implications for the functional anatomy of chorea and
rigidity-akinesia. Ann. Neurol.
27:357-365.
Albin RL, Young AB, and Penney JB (1989).
The functional anatomy of basal ganglia disorders. Trends Neurosci. 12:366-375.
Ambrose CM, Duyao MP, Barnes G, Bates GP,
Lin CS, Srinidhi J, Baxendale S, Hummerich H, Lehrach H, Altherr M, Wasmuth
J, Buckler A, Church D, Housman D, Berks M, Micklem G, Durbin R, Dodge A,
Read A, Gusella J, and Macdonald ME (1994). Structure and expression of the
Huntington's disease gene: Evidence against simple inactivation due to an
expanded CAG repeat. Somat.Cell Mol.Genet.
20:27-38.
Antonini A, Leenders KL, Spiegel R, Meier
D, Vontobel P, Weigell-Weber M, Sanchez-Pernaute R, De Yebenez JG, Boesiger
P, Weindl A, and Maguire RP (1996). Striatal glucose metabolism and dopamine
D2 receptor binding in asymptomatic gene carriers and patients with Huntington's
disease. Brain 119:2085-2095.
Aronin N, Chase K, Young C, Sapp E, Schwarz
C, Matta N, Kornreich R, Landwehrmeyer B, Bird E, Beal MF, Vonsattel JP, Smith
T, Carraway R, Boyce FM, Young AB, Penney JB, and DiFiglia M (1995). CAG expansion
affects the expression of mutant huntingtin in the Huntington's disease brain.
Neuron 15:1193-1201.
Augood SJ, Faull RLM, and Emson PC (1997).
Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's
disease. Ann. Neurol. 42:215-221.
Augood SJ, Faull RLM, Love DR, and Emson
PC (1996). Reduction in enkephalin and substance P messenger RNA in the striatum
of early grade Huntington's disease: a detailed cellular in situ hybridization study. Neuroscience 72:1023-1036.
Avila-Giron R (1973). Medical and social
aspects of Huntington's chorea in the state of Zulia, Venezuela. Adv. Neurol. 1:261-266.
Bao J, Sharp AH, Wagster MV, Becher M, Schilling
G, Ross CA, Dawson VL, and Dawson TM (1996). Expansion of polyglutamine repeat
in huntingtin leads to abnormal protein interactions involving calmodulin.
Proc. Natl. Acad. Sci. (USA) 93:5037-5042.
Barbeau A, Chase TN, and Paulson GW, Eds.
(1973). Huntington's chorea 1872-1972.
Advances in Neurology. New York, Raven Press.
Beal MF, Brouillet E, Jenkins B, Henshaw
R, Rosen B, and Hyman BT (1993a). Age-dependent striatal excitotoxic lesions
produced by the endogenous mitochondrial inhibitor malonate. J. Neurochem. 61:1147-1150.
Beal MF, Brouillet E, Jenkins BG, Ferrante
RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, and Hyman BT (1993b).
Neurochemical and histologic characterization of striatal excitotoxic lesions
produced by the mitochondrial toxin 3-nitropropionaic acid. J.
Neurosci. 13:4181-4192.
Beal MF, Kowall NW, Ellison DW, Mazurek
MF, Swartz KJ, and Martin JB (1986). Replication of the neurochemical characteristics
of Huntington's disease by quinolinic acid. Nature 321:168-171.
Becher MW, Kotzuk JA, Sharp AH, Davies SW,
Bates GP, Price DL, and Ross CA (1998). Intranuclear neuronal inclusions in
Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation
between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol Dis 4:387-97.
Bittigau P and Ikonomidou C (1997). Glutamate
in neurologic diseases. J Child Neurol
12:471-485.
Block-Galarza J, Chase KO, Sapp E, Vaughan
KT, Vallee RB, DiFiglia M, and Aronin N (1997). Fast transport and retrograde
movement of huntingtin and HAP1 in axons. NeuroReport 8:2247-2251.
Bogdanov MB, Ferrante RJ, Kuemmerle S, Klivenyi
P, and Beal MF (1998). Increased vulnerability to 3-nitropropionic acid in
an animal model of Huntington's disease. J Neurochem 71:2642-4.
Borlongan CV, Koutouzis TK, Randall TS,
Freeman TB, Cahill DW, and Sanberg PR (1995). Systemic 3-nitropropionic acid:
Behavioral deficits and striatal damage in adult rats. Brain ResearchBull. 36:549-556.
Boutell JM, Wood JD, Harper PS, and Jones
AL (1998). Huntingtin interacts with cystathionine beta-synthase. Hum. Mol. Genet. 7:371-8.
Brennan WA, Bird ED, and Aprille JR (1985).
Regional mitochondrial respiratory activity in Huntington's disease brain.
J. Neurochem. 44:1948-1950.
Brouillet E, Jenkins BG, Hyman BT, Ferrante
RJ, Kowall NW, Srivastava R, Roy DS, Rosen BR, and Beal MF (1993). Age-dependent
vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic
acid. J. Neurochem. 60:356-359.
Browne SE, Bowling AC, MacGarvey U, Baik
MJ, Berger SC, Muqit MMK, Bird ED, and Beal MF (1997). Oxidative damage and
metabolic dysfunction in Huntington's disease: selective vulneralbility of
the basal ganglia. Ann. Neurol.
41:646-653.
Burke JR, Enghild JJ, Martin ME, Jou YS,
Myers RM, Roses AD, Vance JM, and Strittmatter WJ (1996a). Huntingtin and
DRPLA proteins selectively interact with the enzyme GAPDH. Nat. Med. 2:347-350.
Burke JR, Enghild JJ, Martin ME, Jou YS,
Myers RM, Roses AD, Vance JM, and Strittmatter WJ (1996b). Huntingtin and
DRPLA proteins selectively interact with the enzyme GAPDH [see comments].
Nat Med 2:347-50.
Burright EN, Clark HB, Servadio A, Matilla
T, Feddersen RM, Yunis WS, Duvick LA, Zoghbi HY, and Orr HT (1995). SCA1 transgenic
mice: a model for neurodegeneration caused by an expanded CAG trinucleotide
repeat. Cell 82:937-948.
Butterworth J, Yates CM, and Reynolds GP
(1985). Distribution of phosphate activated glutaminase, succinic dehydrogenase,
pyruvate dehydrogenase and gamma-glutamyl transpeptidase in post mortem brain
from Huntington's disease and agonal cases. J. Neurol. Sci. 67:161-171.
Cha J-HJ, Kosinski CM, Kerner JA, Alsdorf
SA, Mangiarini L, Davies SW, Penney JB, Bates GP, and Young AB (1998). Altered
brain neurotransmitter receptors in transgenic mice expressing a portion of
an abnormal human Huntington disease gene. Proc.
Natl. Acad. Sci. (USA) 95:6480-6485.
Choi DW, Lobner D, and Dugan LL (1998).
Glutamate receptor-mediated neuronal death in the ischemic brain. Ischemic Stroke: from Basic Mechanisms to New
Drug Development. CY Hsu. Basel, Karger. 16:2-13.
Choi DW and Rothman SM (1990). The role
of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu. Rev. Neurosci. 13:171-182.
Conneally PM (1984). Huntington disease:
genetics and epidemiology. Am.J.Hum.Genet.
36:506-526.
Cudkowicz M and Kowall NW (1990). Degeneration
of pyramidal projection neurons in Huntington's disease cortex. Ann. Neurol. 27:200-204.
David G, Abbas N, Stevanin G, Dürr A, Yvert
G, Cancel G, Weber C, Imbert G, Saudou F, Antoniou E, Drabkin H, Gemmill R,
Giunti P, Benomar A, Wood N, Ruberg M, Agid Y, Mandel J-L, and Brice A (1997).
Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat.
Genet. 17:65-70.
Davies SW, Beardsall K, Turmaine M, DiFiglia
M, Aronin N, and Bates GP (1998). Are neuronal intranuclear inclusions the
common neuropathology of triplet-repeat disorders with polyglutamine-repeat
expansions? Lancet 351:131-133.
Davies SW, Turmaine M, Cozens BA, DiFiglia
M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, and Bates GP
(1997). Formation of neuronal intranuclear inclusions underlies the neurological
dysfunction in mice transgenic for the HD mutation. Cell 90:537-48.
de la Monte SM, Vonsattel J-P, and Richardson
Jr. EP (1988). Morphometric demonstration of atrophic changes in the cerebral
cortex, white matter, and neostriatum in Huntington's disease. J. Neuropathol. Exp. Neurol. 47:516-525.
DiFiglia M (1990). Excitotoxic injury of
the neostriatum: a model for Huntington's disease. Trends Neurosci. 13:286-289.
DiFiglia M, Sapp E, Chase K, Schwarz C,
Meloni A, Young C, Martin E, Vonsattell J-P, Carraway R, Reeves SA, Boyce
FM, and Aronin N (1995). Huntingtin is a cytoplasmic protein asociated with
vesicles in human and rat brain neurons. Neuron
14:1075-1081.
DiFiglia M, Sapp E, Chase KO, Davies SW,
Bates GP, Vonsattel JP, and Aronin N (1997). Aggregation of huntingtin in
neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990-1993.
Dragatsis I, Efstratiadis A, and Zeitlin
A (1998). Mouse mutant embryos lacking huntingtin are rescued from lethality
by wild-type extraembryonic tissues. Development
125:1529-39.
Dragunow M, Faull RLM, Lawlor P, Beilharz
EJ, Singleton K, Walker EB, and Mee E (1995). In situ evidence for DNA fragmentation
in Huntington's disease striatum and Alzheimer's disease temporal lobes. neuroreport
6:1053-1057.
Durbach N and Hayden MR (1993). George Huntington:
The man behind the eponym. J Med Genet.
30:406-409.
Dure LS, IV, Young AB, and Penney JB (1991).
Excitatory amino acid binding sites in the caudate nucleus and frontal cortex
of Huntington's disease. Ann. Neurol.
30:785-793.
Duyao MP, Ambrose CM, Myers RH, Novoletto
A, Persichetti F, Frontali M, Folstein SE, Ross C, Franz ML, Abbott M, Gray
J, Conneally PM, Young A, Penney J, Hollingsworth Z, Shoulson I, Lazzarini
AM, Falek A, Koroshetz W, Sax DS, Bird E, Vonsattel JP, Bonilla E, Alvir J,
Bickham Conde J, Cha J-H, Dure L, Gomez F, Ramos M, Sanchez-Ramos J, Snodgrass
SR, de Young M, Moscowitz C, Penchaszadeh G, MacFarlane H, Anderson MA, Jenkins
B, Srinidhi J, Barnes G, Gusella JF, and MacDonald ME (1993). Trinucleotide
repeat length instability and age of onset in Huntington's disease. Nat. Genet. 4:387-392.
Faber PW, Barnes GT, Srinidhi J, Chen J,
Gusella JF, and MacDonald ME (1998). Huntingtin interacts with a family of
WW domain proteins. Hum. Mol. Genet.
7:1463-74.
Fagg GE, Foster AC, and Ganong AH (1986).
Excitatory amino acid synaptic mechanisms and neurological function. Trends Pharmacol. Sci. ?:357-363.
Feigin A, Kieburtz K, Como P, Hickey C,
Claude K, Abwender D, Zimmerman C, Steinberg K, and Shoulson I (1996). Assessment
of coenzyme Q10 tolerability in Huntington's disease. Mov. Disord. 11:321-323.
Ferrante RJ, Beal MF, Kowall NW, Richardson
EP, and Martin JB (1987a). Sparing of acetylcholinesterase-containing striatal
neurons in Huntington's disease. Brain Res. 411:162-166.
Ferrante RJ, Gutekunst CA, Persichetti F,
McNeil SM, Kowall NW, Gusella JF, MacDonald ME, Beal MF, and Hersch SM (1997).
Heterogeneous topographic and cellular distribution of huntingtin expression
in the normal human neostriatum. J Neurosci
17:3052-63.
Ferrante RJ, Kowall NW, Beal MF, Martin
JB, Bird ED, and Richardson EP (1987b). Morphologic and histochemical characteristics
of a spared subset of striatal neurons in Huntington's disease. J.Neuropathol.Experimental
Neurology 46(1):12-27.
Folstein S (1989). Huntington's disease: A disorder of families. Baltimore, Johns Hopkins
University Press.
Gerber H-P, Seipel K, Georgiev O, Höfferer
M, Hug M, Rusconi S, and Schaffner W (1994). Transcriptional activation modulated
by homopolymeric glutamine and proline stretches. Science 263:808-811.
Goff DC and Wine L (1997). Glutamate in
schizophrenia: clinical and research
implications. Schizophr Res 27:157-168.
Goldberg YP, Kremer B, Andrew SE, Theilmann
J, Graham RK, Squitieri F, Telenius H, Adam S, Sajoo A, Starr E, Heiberg A,
Wolff G, and Hayden MR (1993). Molecular analysis of new mutations for Huntington's
disease: Intermediate alleles and sex of origin effects. Nat. Genet. 5:174-179.
Goldberg YP, McMurray CT, Zeisler J, Almqvist
E, Sillence D, Richards F, Gacy AM, Buchanan J, Telenius H, and Hayden MR
(1995). Increased instability of intermediate alleles in families with sporadic
Huntington disease compared to similar sized intermediate alleles in the general
population. Hum. Mol. Genet. 4:1911-8.
Graybiel AM (1990). Neurotransmitters and
neuromodulators in the basal ganglia. Trends
Neurosci. 13:244-254.
Greene JG and Greenamyre JT (1995). Characterization
of the excitotoxic potential of the reversible succinate dehydrogenase inhibitor
malonate. J. Neurochem. 64:430-436.
Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper
JM, and Schapira AHV (1996). Mitochondrial defect in Huntington's disease
caudate nucleus. Ann. Neurol. 39:385-389.
Gusella JF, Tanzi RE, Bader PI, Phelan MC,
Stevenson R, Hayden MR, Hofman KJ, Faryniarz AG, and Gibbons K (1985). Deletion
of Huntington's disease-linked G8 (D4S10) locus in Wolf-Hirschhorn syndrome.
Nature 318:75-78.
Gusella JF, Wexler NS, Conneally PM, Naylor
SL, Anderson MA, Tanzi RE, Watkins PC, Ottina K, Wallace MR, Sakaguchi AY,
Young AB, Shoulson I, Bonilla E, and Martin JB (1983). A polymorphic DNA marker
genetically linked to Huntington's disease. Nature 306:234-238.
Gutekunst C-A, Levey AI, Heilman CJ, Whaley
WL, Yi H, Nash NR, Rees HD, Madden JJ, and Hersch SM (1995a). Identification
and localization of huntingtin in brain and human lymphoblatoid cell lines
with anti-fusion protein antibodies. Proc. Natl. Acad. Sci. (USA) 92:8710-8714.
Gutekunst CA, Levey AI, Heilman CJ, Whaley
WL, Yi H, Nash NR, Rees HD, Madden JJ, and Hersch SM (1995b). Identification
and localization of huntingtin in brain and human lymphoblastoid cell lines
with anti-fusion protein antibodies. Proc Natl Acad Sci U S A 92:8710-4.
Harper PS, Ed. (1996). Huntington's Disease. Major Problems in
Neurology. Philadelphia, W. B. Saunders Co.
Hayden MR (1981). Huntington's Chorea. New York, Springer-Verlag.
Hedreen JC and Folstein SE (1995). Early
loss of neostriatal striosome neurons in Huntington's disease. J Neuropathol.Experimental Neurology 54:105-120.
Hedreen JC, Peyser CE, Folstein SE, and
Ross CA (1991). Neuronal loss in layers V and VI of cerebral cortex in Huntington's
disease. Neurosci. Lett. 133:257-261.
Henshaw R, Jenkins BG, Schulz JB, Ferrante
RJ, Kowall NW, Rosen BR, and Beal MF (1994). Malonate produces striatal lesions
by indirect NMDA receptor activation. Brain Res. 647:161-166.
Hodgson JG, Smith DJ, McCutcheon K, Koide
HB, Nishiyama K, Dinulos MB, Stevens ME, Bissada N, Nasir J, Kanazawa I, Disteche
CM, Rubin EM, and Hayden MR (1996). Human huntingtin derived from YAC transgenes
compensates for loss of murine huntingtin by rescue of the embryonic lethal
phenotype. Hum. Mol. Genet. 5:1875-1885.
Huntington G (1872). On chorea. Medical and Surgical Report 1872 26:317-321.
Huntington's Disease Collaborative Research
Group (1993). A novel gene containing a trinucleotide repeat that is unstable
in Huntington's disease chromosomes. Cell 72:971-983.
Ikeda H, Yamaguchi M, Sugai S, Aze Y, Narumiya
S, and Kakizuka A (1996). Expanded polyglutamine in the Machado-Joseph disease
protein induces cell death in vitro
and in vivo. Nat. Genet. 13:196-202.
James CM, Houlihan GD, Snell RG, Cheadle
JP, and Harper PS (1994). Late-onset Huntington's disease: a clinical and
molecular study. Age Ageing 23:445-8.
Jenkins BG, Koroshetz WJ, Beal MF, and Rosen
BR (1993). Evidence for impairment of energy metabolisn in vivo in Huntington's
disease using localized 1H NMR spectroscopy. Neurology 43:2689-2695.
Kahlem P, Green H, and Djian P (1998). Transglutaminase
action imitates Huntington's disease: selective polymerization of Huntingtin
containing expanded polyglutamine. Mol Cell 1:595-601.
Kahlem P, Terré C, Green H, and Djian P
(1996). Peptides containing glutamine repeats as substrates for transglutaminase-catalyzed
cross-linking: relevance to diseases of the nervous system. Proc.
Natl. Acad. Sci. (USA) 93:14580-14585.
Karlin S and Burge C (1996). Trinucleotide
repeats and long homopeptides in genes and proteins associated with nervous
system disease and development. Proc. Natl. Acad. Sci. (USA) 93:1560-1565.
Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa
M, Inoue M, Katayama S, Kawakami H, Nakamura S, Nishimura M, Akiguchi I, and
et al. (1994). CAG expansions in a novel gene for Machado-Joseph disease at
chromosome 14q32.1 [see comments]. Nat
Genet 8:221-8.
Kawaguchi Y, Wilson CJ, Augood SJ, and Emson
PC (1995). Striatal interneurones: chemical, physiological and morphological
characterization. Trends Neurosci.
18:527-535.
Kieburtz K, Feigin A, McDermott M, Como
P, Abwender D, Zimmerman C, Hickey C, Orme C, Claude K, Sotack J, Greenamyre
JT, Dunn C, and Shoulson I (1996). A controlled trial of remacemide hydrochloride
in Huntington's disease. Mov. Disord.
11:273-277.
Kim M, Lee HS, LaForet G, McIntyre C, Martin
EJ, Chang P, Kim TW, Williams M, Reddy PH, Tagle D, Boyce FM, Won L, Heller
A, Aronin N, and DiFiglia M (1999). Mutant huntingtin expression in clonal
striatal cells: dissociation of inclusion formation and neuronal survival
by caspase inhibition. J Neurosci
19:964-73.
Klockgether T and Turski L (1993). Toward
an understanding of the role of glutamate in experimental Parkinsonism: agonist-sensitive
sites in the basal ganglia. Ann. Neurol. 34:585-593.
Koide R, Ikeuchi T, Onodera O, Tanaka H,
Igarashi S, Endo K, Takahashi H, Kondo R, Ishikawa A, Hayashi T, Saito M,
Tomoda A, Miike T, Naito H, Ikuta F, and Tsuji S (1994). Unstable expansion
of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA).
Nat. Genet. 6:9-13.
Kornbuber J and Wiltfang J (1998). The role
of glutamate in dementia. J Neural Transm
53:277-287.
Koroshetz WJ, Jenkins BG, Rosen BR, and
Beal MF (1997). Energy metabolism defects in Huntington's disease and effects
of coenzyme Q10.
Ann. Neurol. 41:160-165.
Kosinski CM, Cha JH, Young AB, Persichetti
F, MacDonald M, Gusella JF, Penney JB, and Standaert DG (1997). Huntingtin
immunoreactivity in the rat neostriatum: differential accumulation in projection
and interneurons. Exp. Neurol. 144:239-247.
Kuhl DE, Markham CH, Metter EJ, Riege WH,
Phelps ME, and Mazziotta JC (1985). Local cerebral glucose utilization in
symptomatic and presymptomatic Huntingtons disease. Brain Img.Brain Func. 2:199-209.
La Spada AR, Wilson EM, Lubahn DB, Harding
AE, and Fischbeck KH (1991). Androgen receptor gene mutations in X-linked
spinal and bulbar muscular atrophy. Nature 352:77-9.
Landwehrmeyer GB, McNeil SM, Dure LS, Ge
P, Aizawa H, Huang Q, Ambrose CM, Duyao MP, Bird ED, Bonilla E, De Young M,
Avila-Gonzales AJ, Wexler NS, DiFiglia M, Gusella JF, Macdonald ME, Penney
JB, Young AB, and Vonsattel JP (1995). Huntington's disease gene: Regional
and cellular expression in brain of normal and affected individuals. Ann. Neurol. 37:218-230.
Leeflang EP, Zhang L, Tavare S, Hubert R,
Srinidhi J, Macdonald ME, Myers RH, De Young M, Wexler NS, Gusella JF, and
Arnheim N (1995). Single sperm analysis of the trinucleotide repeats in the
Huntington's disease gene: Quantification of the mutation frequency spectrum.
Hum. Mol. Genet. 4:1519-1526.
Li SH, Schilling G, Young WS, III, Li XJ,
Margolis RL, Stine OC, Wagster MV, Abbott MH, Franz ML, Ranen NG, Folstein
SE, Hedreen JC, and Ross CA (1993). Huntington's disease gene (IT15) is widely
expressed in human and rat tissues. Neuron
11:985-993.
Li XJ, Sharp AH, Li SH, Dawson TM, Snyder
SH, and Ross CA (1996). Huntingtin-associated protein (HAP1): Discrete neuronal
localizations in the brain resemble those of neuronal nitric oxide synthase.
Proceedings of the National Academy of Sciences,
U.S.A.. 93:4839-4844.
London ED, Yamamura HI, Bird ED, and Coyle
JT (1981). Decreased receptor-binding sites for kainic acid in brains of patients
with Huntington's disease. Biol. Psychiatry
16:155-162.
Lorand L (1996). Neurodegenerative diseases
and transglutaminase. Proc. Natl. Acad.
Sci. (USA) 93:14310-14313.
MacDonald ME, Barnes G, Srinidhi J, Duyao
MP, Ambrose CM, Myers RH, Gray J, Conneally PM, Young A, Penney J, Shoulson
I, Hollingsworth Z, Koroshetz W, Bird E, Vonsattel JP, Bonilla E, Moscowitz
C, Penchaszadeh G, Brzustowicz L, Alvir J, Bickham Conde J, Cha JH, Dure L,
and Gomez F (1993). Gametic but not somatic instability of CAG repeat length
in Huntington's disease. J. Med. Genet.
30:982-986.
Mangiarini L, Sathasivam K, Seller M, Cozens
B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, and
Bates GP (1996). Exon 1 of the HD
gene with an expanded CAG repeat is sufficient to cause a progressive neurological
phenotype in transgenic mice. Cell
87:493-506.
Mann VM, Cooper JM, Javoy-Agid F, Agid Y,
Jenner P, and Schapira AH (1990). Mitochondrial function and parental sex
effect in Huntington's disease. Lancet
336:749.
Mazziotta JC, Phelps ME, Pahl JJ, Huang
SC, Baxter LR, Riege WH, Hoffman JM, Kuhl DE, Lanto AB, Wapenski JA, and Markham
CH (1987). Reduced cerebral glucose metabolism in asymptomatic subjects at
risk for Huntington's disease. N. Engl.
J. Med. 316:357-362.
Myers RH, Macdonald ME, Koroshetz WJ, Duyao
MP, Ambrose CM, Taylor SAM, Barnes G, Srinidhi J, Lin CS, Whaley WL, Lazzarini
AM, Schwarz M, Wolff G, Bird ED, Vonsattel JPG, and Gusella JF (1993). De
novo expansion of a (CAG)n repeat in sporadic Huntington's disease. Nat. Genet. 5:168-173.
Nasir J, Floresco SB, O'Kusky JR, Diewert
VM, Richman JM, Zeisler J, Borowski A, Marth JD, Phillips AG, and Hayden MR
(1995). Targeted disruption of the Huntington's disease gene results in embryonic
lethality and behavioral and morphological changes in heterozygotes. Cell 81:811-823.
Negrette A (1958). Corea de Huntington. Maracaibo, Venezuela, University of Zulia.
Ordway JM, Tallaksen-Greene S, Gutekunst
C-A, Bernstein EM, Cearley JA, Wiener HW, Dure IV LS, Lindsey R, Hersch SM,
Jope RS, Albin RL, and Detloff PJ (1997). Ectopically expressed CAG repeats
cause intranuclear inclusions and a progressive late onset neurological phenotype
in the mouse. Cell 91:753-763.
Orr HT, Chung MY, Banfi S, Kwiatkowski TJ,
Jr., Servadio A, Beaudet AL, McCall AE, Duvick LA, Ranum LP, and Zoghbi HY
(1993). Expansion of an unstable trinucleotide CAG repeat in spinocerebellar
ataxia type 1. Nat Genet 4:221-6.
Palfi SP, Ferrante RJ, Brouillet E, Beal
MF, Dolan R, Guyot MC, Peschanski M, and Hantraye P (1996). Chronic 3-nitropropionic
acid treatment in baboons replicates the cognitive and motor deficits of Huntington's
disease. J. Neurosci. 16:3019-3025.
Parker WD, Jr., Boyson SJ, Luder AS, and
Parks JK (1990). Evidence for a defect in NADH:ubiquinone oxidoreductase (complex
I) in Huntington's disease. Neurology
40:1231-1234.
Patel J and Zinkand WC (1994). Role of metabotropic
glutamate receptors in neuronal degeneration. The Metabotropic Glutamate Receptors. PJ Conn and J Patel. Totowa,
NJ, Humana Press:231-242.
Paulson HL and Fischbeck KH (1996). Trinucleotide
repeats in neurogenetic disorders. Annu. Rev. Neurosci. 19:79-107.
Paulson HL, Perez MK, Trottier Y, Trojanowski
JQ, Subramony SH, Das SS, Vig P, Mandel JL, Fischbeck KH, and Pittman RN (1997).
Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar
ataxia type 3. Neuron 19:333-44.
Penney JB, Jr., Vonsattel JP, MacDonald
ME, Gusella JF, and Myers RH (1997). CAG repeat number governs the development
rate of pathology in Huntington's disease [see comments]. Ann Neurol 41:689-92.
Penney JB, Young AB, Shoulson I, Starosta-Rubenstein
S, Snodgrass SR, Sanchez-Ramos J, Ramos-Arroyo M, Gomea F, Penchaszadeh G,
Alvir J, Esteves J, DeQuiroz I, Marsol N, Moreno H, Conneally L, Bonilla E,
and Wexler NS (1990). Huntington's Disease in Venezuela: 7 Years of Follow-up
on Symptomatic and Asymptomatic Individuals. Mov. Disord. 5:93-99.
Perry TL, Hansen S, and Kloster M (1973).
Huntington's chorea: deficiency of
gamma-aminobutyric acid in brain. N.
Engl. J. Med. 288:337-342.
Persichetti F, Ambrose CM, Ge P, McNeil
SM, Srinidhi J, Anderson MA, Jenkins B, Barnes GT, Duyao MP, Kanaley L, and
et al. (1995). Normal and expanded Huntington's disease gene alleles produce
distinguishable proteins due to translation across the CAG repeat. Mol Med 1:374-83.
Perutz MF (1995). Glutamine repeats as polar
zippers: their role in inherited neurodegenerative disease. Mol Med 1:718-21.
Perutz MF (1996). Glutamine repeats and
inherited neurodegenerative diseases: molecular aspects. Curr. Opin. Struct. Biol. 6:848-858.
Perutz MF, Johnson T, Suzuki M, and Finch
JT (1994). Glutamine repeats as polar zippers: their possible role in inherited
neurodegenerative diseases. Proc. Natl.
Acad. Sci. (USA) 91:5355-5358.
Portera-Cailliau C, Hedreen JC, Price DL,
and Koliatsos VE (1995). Evidence for apoptotic cell death in Huntington disease
and excitotoxic animal models. J. Neurosci.
15:3775-3787.
Pulst SM, Nechiporuk A, Nechiporuk T, Gispert
S, Chen X-N, Lopes-Cendes I, Pearlman S, Starkman S, Orozco-Diaz G, Lunkes
A, DeJong P, Rouleau GA, Auburger G, Korenberg JR, Figueroa C, and Sahba S
(1996). Moderate expansion of a normally biallelic trinucleotide repeat in
spinocerebellar ataxia type 2. Nat.
Genet. 14:269-276.
Ranen NG, Peyser CE, and Folstein SE (1993).
A Physician's Guide to the Management
of Huntington's Disease: Pharmacologic and Non-Pharmacologic Interventions.
New York, Huntington's Disease Society of America.
Reddy PH, Williams M, Charles V, Garrett
L, Pike-Buchanan L, Whetsell WO, Miller G, and Tagle DA (1998a). Behavioral
abnormalities and selective neuronal loss in HD transgenic mice expressing
mutated full-length HD cDNA. Nat. Genet.
20:198-202.
Reddy PH, Williams M, Charles V, Garrett
L, Pike-Buchanan L, Whetsell WO, Jr., Miller G, and Tagle DA (1998b). Behavioural
abnormalities and selective neuronal loss in HD transgenic mice expressing
mutated full-length HD cDNA. Nat Genet
20:198-202.
Reiner A, Albin RL, Anderson KD, D'Amato
CJ, Penney JB, and Young AB (1988). Differential loss of striatal projection
neurons in Huntington disease. Proceedings
of the National Academy of Sciences U.S.A. 85:5733-5737.
Richfield EK, O'Brien CF, Eskin T, and Shoulson
I (1991). Heterogeneous dopamine receptor changes in early and late Huntington's
disease. Neurosci. Lett. 132:121-126.
Robinson MB and Coyle JT (1987). Glutamate
and related acidic excitatory neurotransmitters: from basic science to clinical
application. FASEB J. 1:446-455.
Roizin L, Kaufman N, Wilson S, Stellar S,
and Liu JC (1976). Neuropathologic observations in Huntington's chorea. Progress in Neuropathology III. HM Zimmerman.
New York, Grune and Stratton:447-488.
Roizin L, Stellar S, and Liu JC (1979).
Neuronal nuclear-cytoplasmic changes in Huntington's chorea: electron microscope
investigations. Advances in Neurology.
TN Chase, NS Wexler and A Barbeau. New York, Raven Press. 23:95-122.
Ross CA (1997). Intranuclear neuronal inclusions:
a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases?
Neuron 19:1147-1150.
Saudou F, Finkbeiner S, Devys D, and Greenberg
ME (1998). Huntingtin acts in the nucleus to induce apoptosis but death does
not correlate with the formation of intranuclear inclusions. Cell 95:55-66.
Schapira AHV, Tabrizi SJ, Cleeter M, Xuereb
J, and Cooper JM (1997). Biochemical abnormalities in Huntington's disease
brain. 17th International Meeting of the World Federation of Neurology Research
Group on Huntington's Disease, Syndey, Australia.
Scherzinger E, Lurz R, Turmaine M, Mangiarini
L, Hollenbach B, Hasenbank R, Bates GP, Davies SW, Lehrach H, and Wanker EE
(1997). Huntingtin-encoded polyglutamine expansions form amyloid-like protein
aggregates in vitro and in vivo. Cell
90:549-58.
Shoulson I (1998). Experimental therapeutics
of neurodegenerative disorders: unmet needs. Science 282:1072-1074.
Sittler A, Walter S, Wedemeyer N, Hasenbank
R, Scherzinger E, Eickhoff H, Bates GP, Lehrach H, and Wanker EE (1998). SH3GL3
associates with the Huntingtin exon 1 protein and promotes the formation of
polygln-containing protein aggregates. Mol
Cell 2:427-36.
Skinner PJ, Koshy B, Cummings CJ, Klement
IA, Helin K, Servadio A, Zoghbi HY, and Orr HT (1997). Ataxin-1 with an expanded
glutamine tract alters nuclear matrix-associated structures. Nature 389:971-974.
Snell RG, MacMillan JC, Cheadle JP, Fenton
I, Lazarou LP, Davies P, Macdonald ME, Gusella JF, Harper PS, and Shaw DJ
(1993). Relationship between trinucleotide repeat expansion and phenotypic
variation in Huntington's disease. Nat.
Genet. 4:393-397.
Strong TV, Tagle DA, Valdes JM, Elmer LW,
Boehm K, Swaroop M, Kaatz K, Collins FS, and Albin RL (1993). Widespread expression
of the human and rat Huntington's disease gene in brain and nonneuronal tissues.
Nat. Genet. 5:259-265.
Taylor-Robinson SD, Weeks RA, Bryant DJ,
Sargentoni J, Marcus CD, Harding AE, and Brooks DJ (1996). Proton magnetic
resonance spectroscopy in Huntington's disease: Evidence in favour of the
glutamate excitotoxic theory? Mov. Disord.
11:167-173.
Telenius H, Kremer B, Goldberg YP, Theilmann
J, Andrew SE, Zeisler J, Adam S, Greenberg C, Ives EJ, Clarke LA, and Hayden
MR (1994). Somatic and gonadal mosaicism of the Huntington disease gene CAG
repeat in brain and sperm. Nat. Genet.
6:409-414.
Telenius H, Kremer HPH, Theilmann J, Andrew
SE, Almqvist E, Anvret M, Greenberg C, Greenberg J, Lucotte G, Squitieri F,
Starr E, Goldberg YP, and Hayden MR (1993). Molecular analysis of juvenile
Huntington disease: The major influence on (CAG)n repeat length is the sex
of the affected parent. Hum.Mol.Genet.
2:1535-1540.
Thomas LB, Gates DJ, Richfield EK, O'Brien
TF, Schweitzer JB, and Steindler DA (1995). DNA end labeling (TUNEL) in Huntington's
disease and other neuropathological conditions. Exp. Neurol. 133:265-272.
Vonsattel JP, Myers RH, Stevens TJ, Ferrante
RJ, Bird ED, and Richardson EP (1985). Neuropathological classification of
Huntington's disease. J. Neuropathol.
Exp. Neurol. 44:559-577.
Wanker EE, Rovira C, Scherzinger E, Hasenbank
R, Walter S, Tait D, Colicelli J, and Lehrach H (1997). HIP-I: a huntingtin
interacting protein isolated by the yeast two-hybrid system. Hum. Mol. Genet. 6:487-495.
Weeks RA, Piccini P, Harding AE, and Brooks
DJ (1996). Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation
carriers of Huntington's disease. Ann.
Neurol. 40:49-54.
Wexler NS, Rose EA, and Housman DE (1991).
Molecular approaches to hereditary diseases of the nervous system: Huntington's disease as a paradigm. Annu. Rev. Neurosci. 14:503-529.
White JK, Auerbach W, Duyao MP, Vonsattel
JP, Gusella JF, Joyner AL, and MacDonald ME (1997). Huntingtin is required
for neurogenesis and is not impaired by the Huntington's disease CAG expansion.
Nat. Genet. 17:404-410.
Wuellner U, Young AB, Penney JB, and Beal
MF (1994). 3-nitropropionic acid toxicity in the striatum. J. Neurochem. 63:1772-1781.
Young AB (1994). Huntington's disease: lessons
from and for molecular neuroscience. The Neuroscientist preview
issue:30-37.
Young AB, Greenamyre JT, Hollingsworth Z,
Albin R, D'Amato C, Shoulson I, and Penney JB (1988). NMDA receptor losses
in putamen from patients with Huntington's disease. Science 241:981-983.
Young AB, Penney JB, Starosta-Rubenstein
S, Markel DS, Berent S, Giordani B, Ehrenkaufer R, Jewett D, and Hichwa R
(1986a). Pet scan investigations of Huntington's disease: cerebral metabolic
correlates of neurological features and functional decline. Ann. Neurol. 20:296-303.
Young AB, Shoulson I, Penney JB, Starosta
S, Gomez F, Travers H, Ramos-Arroyo MA, Snodgrass SR, Bonilla E, Moreno H,
and Wexler NS (1986b). Huntington's disease in Venezuela: neurologic features
and functional decline. Neurology
36:244-249.
Young AB, Shoulson I, Penney JB, Starosta-Rubinstein,
Gomex F, Travers H, Ramos-Arroyo MA, Snodgrass SR, Bonilla E, Moreno H, and
Wexler NS (1986c). Huntington's disease in Venezuela: neurologic features
and functional decline. Neurology
36:244-249.
Zeitlin S, Liu JP, Chapman DL, Papaioannou
VE, and Efstratiadis A (1995). Increased apoptosis and early embryonic lethality
in mice nullizygous for the Huntington's disease gene homologue. Nat.
Genet. 11:155-163.
Zhuchenko O, Bailey J, Bonnen P, Ashizawa
T, Stockton DW, Amos C, Dobyns WB, Subramony SH, Zoghbi HY, and Lee CC (1997).
Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine
expansions in the a1A-voltage-dependent calcium channel. Nat. Genet. 15:62-69.
Zuhlke C, Riess O, Bockel B, Lange H, and
Thies U (1993). Mitotic stability and meiotic variability of the (CAG)n repeat
in the Huntington disease gene. Hum.
Mol. Genet. 2:2063-7.
published 2000